Noven
Pharmaceuticals, Inc., headquartered in Miami, Florida, has established
itself as a leading developer of advanced transdermal drug delivery
technologies and prescription transdermal products. Its commercialized
transdermal products include Vivelle-Dot® (estradiol transdermal
system), the most prescribed estrogen patch in the U.S., and Daytrana® (methylphenidate
transdermal system), the first and only patch approved for the treatment
of ADHD.
With the acquisition of JDS Pharmaceuticals in August 2007,
Noven has become a broader-based specialty pharmaceutical company with
a substantially enhanced late-stage product pipeline and the infrastructure,
products and category expertise to market and sell its own products.
Products
currently marketed through the Noven/JDS sales infrastructure consist
of Pexeva® (paroxetine mesylate) and Lithobid® (lithium
carbonate). Developmental products in psychiatry consist of Stavzor™ (delayed
release valproic acid softgel), Lithium QD (once-daily lithium carbonate),
and Stavzor™ ER (extended release valproic acid softgel). The
development pipeline in women’s health consists of Mesafem™ (low-dose
paroxetine mesylate), a non-hormonal product entering Phase 3 clinical
trials for vasomotor symptoms (hot flashes).
Copyright © 2008 Noven Pharmaceuticals, Inc. All rights reserved.